NICE is unable to make a recommendation on bezlotoxumab (Zinplava) for preventing recurrent Clostridium difficile infection in adults because Merck Sharp & Dohme did not provide an evidence submission.

Is this guidance up to date?

We reviewed the evidence in February 2020. We will withdraw this appraisal when the guideline on Clostridium difficile infection: antimicrobial prescribing is published, which will make recommendations on bezlotoxumab.

Guidance development process

How we develop NICE technology appraisal guidance

  • National Institute for Health and Care Excellence (NICE)